全文获取类型
收费全文 | 1084968篇 |
免费 | 74132篇 |
国内免费 | 1381篇 |
专业分类
耳鼻咽喉 | 15069篇 |
儿科学 | 35096篇 |
妇产科学 | 29065篇 |
基础医学 | 154863篇 |
口腔科学 | 29685篇 |
临床医学 | 96861篇 |
内科学 | 205399篇 |
皮肤病学 | 24556篇 |
神经病学 | 82568篇 |
特种医学 | 43179篇 |
外国民族医学 | 201篇 |
外科学 | 164068篇 |
综合类 | 21968篇 |
现状与发展 | 1篇 |
一般理论 | 287篇 |
预防医学 | 76569篇 |
眼科学 | 24648篇 |
药学 | 86926篇 |
8篇 | |
中国医学 | 2825篇 |
肿瘤学 | 66639篇 |
出版年
2019年 | 8107篇 |
2018年 | 11709篇 |
2017年 | 9149篇 |
2016年 | 10422篇 |
2015年 | 11616篇 |
2014年 | 15726篇 |
2013年 | 22847篇 |
2012年 | 31576篇 |
2011年 | 33367篇 |
2010年 | 19462篇 |
2009年 | 18264篇 |
2008年 | 30806篇 |
2007年 | 32972篇 |
2006年 | 33567篇 |
2005年 | 31833篇 |
2004年 | 30500篇 |
2003年 | 29237篇 |
2002年 | 28143篇 |
2001年 | 60140篇 |
2000年 | 61541篇 |
1999年 | 51026篇 |
1998年 | 12555篇 |
1997年 | 11072篇 |
1996年 | 11079篇 |
1995年 | 10387篇 |
1994年 | 9404篇 |
1993年 | 8919篇 |
1992年 | 37842篇 |
1991年 | 36305篇 |
1990年 | 35769篇 |
1989年 | 34307篇 |
1988年 | 30886篇 |
1987年 | 30014篇 |
1986年 | 28244篇 |
1985年 | 26466篇 |
1984年 | 19194篇 |
1983年 | 16131篇 |
1982年 | 8840篇 |
1979年 | 17043篇 |
1978年 | 11409篇 |
1977年 | 10231篇 |
1976年 | 8839篇 |
1975年 | 10073篇 |
1974年 | 11657篇 |
1973年 | 11281篇 |
1972年 | 10758篇 |
1971年 | 10097篇 |
1970年 | 9255篇 |
1969年 | 8944篇 |
1968年 | 7922篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
1.
2.
Hassen Lena M. Albarrak Rana A. Albahlal Reem A. Alsaqabi Dimah K. Hassen Ikhlass M. Daghestani Maha H. Alqurtas Eman M. Alkhalaf Abdulaziz T. Bedaiwi Mohammed K. Omair Mohammed A. Almaghlouth Ibrahim A. 《Quality of life research》2022,31(11):3229-3239
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional... 相似文献
3.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
4.
5.
6.
7.
8.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献
9.
10.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献